Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

148.88 +0.16 (+0.11%)
Streaming Delayed Price Updated: 10:48 AM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
93 94 Next >
7 Defensive Stocks to Build a Moat Around Your Portfolio
Although the market seems to continuously be on the rise, some concerning data suggests investors should consider defensive stocks. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &... 
Via Benzinga
Exposures Product Safety
Guardians of Your Golden Years: 7 Stocks Every Retiree Needs to Own
Investing in your golden years is about choosing stocks for retirees that are low-risk, offer passive income and steadily grow. 
Via InvestorPlace
Analyzing NYSE:JNJ's Dividend Potential.
Why JOHNSON & JOHNSON (NYSE:JNJ) qualifies as a good dividend investing stock. 
Via Chartmill
Insights Into Johnson &amp; Johnson's Performance Versus Peers In Pharmaceuticals Sector
Via Benzinga
Johnson & Johnson Unusual Options Activity For March 08
Via Benzinga
Meet the "Magnificent Seven" Stock That Pays More Dividends Than Any Other U.S.-Based Company
Microsoft is the complete package. 
Via The Motley Fool
Johnson & Johnson Stock Is Great. Here's Why You Shouldn't Buy It.
Johnson & Johnson's days of being a top healthcare stock could be long gone. 
Via The Motley Fool
The Taxman Cometh: 3 Stocks to Soften the Blow and Grow Your Dough
Dive into tax season stocks, featuring dividend-rich JNJ and EQIX, plus growth-focused TSLA, for a smarter tax season strategy. 
Via InvestorPlace
Why Abbott's Formula-Related Sell-Off Could Be A Buying Opportunity, Says Analyst
Fellow infant formula maker Reckitt Benckiser was ordered to pay $60 million to a mother whose baby died after eating Enfamil. 
Via Investor's Business Daily
Topics Death
Exposures Death
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
Amidst regulatory challenges, WuXi AppTec faces backlash from industry giants. Biotechnology Innovation Organization cuts ties, citing national security concerns. Shares plummet as U.S. bills target... 
Via Benzinga
German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits
Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the controversial tactic and its potential implications. 
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Glyphosate Legal
The 3 Most Undervalued Healthcare Stocks to Buy in March 2024
Wager on these promising undervalued healthcare stocks, catering to investors aiming to leverage growth within the dynamic healthcare space. 
Via InvestorPlace
Top Stock Reports For UnitedHealth, Johnson & Johnson & Oracle
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc. (UNH), Johnson & Johnson (JNJ) and Oracle Corp. (ORCL). 
Via Talk Markets
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into... 
Via Benzinga
Exposures Product Safety
3 No-Brainer Stocks to Buy With $300 Right Now
A reasonably modest amount of money can go a long way when it's put to work in historically cheap, industry-leading businesses. 
Via The Motley Fool
7 High-Quality Blue-Chip Stocks to Buy if You’re Looking for Stability
With the market facing a possible rotation out of hot tech names, these stable blue-chip stocks may offer investors confidence. 
Via InvestorPlace
Golden Cross Alert: Johnson & Johnson Shines With Ambrx Deal, Bullish Technical Signal
Johnson & Johnson stock down 1.22% in 6 months, up 5.57% in a year, and 3% YTD. Recent acquisition of Ambrx Biopharma boosts stock. Golden Cross signals trend reversal. 
Via Benzinga
3 Must-Have Dividend Kings for a Steady Income Stream
Discover the dividend kings with constant growth, dominating pharmaceuticals, household products and biotechnology industries. 
Via InvestorPlace
2 High-Yield Dow Jones Dividend Stocks to Buy Now and Hold Forever
These industry leaders boast advantages that could expand their bottom lines for decades. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
The Dow’s Best Friends: 3 ‘Dogs’ Ready to Fetch Huge Returns
The Dogs of the Dow strategy is one of the best yearly strategies investors should use to make some good money. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Wall Street Favorites: Why Analysts Love These 3 Blue-Chip Stocks
Blue-chip stocks are known for their quality, stablility and consistency, which you'll find in all three of these top-notch growth stocks. 
Via InvestorPlace
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
These are some of the best-performing stocks in what's arguably society's most important industry. 
Via The Motley Fool
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung... 
Via Talk Markets
Exposures Product Safety
The Top 3 Pharma Stocks to Buy in March2024
Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge. 
Via InvestorPlace
3 Dividend Aristocrat Stocks to Buy And Hold: March 2024
Buy-and-holder investors should fill their portfolios with these dividend aristocrat stocks to buy. These are some of the top names in the market. 
Via InvestorPlace
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
The Top 3 Healthcare Stocks to Buy in March 2024
There are still bargains to be had in the medical space. These are three top healthcare stocks to buy today. 
Via InvestorPlace
The Top 3 Blue-Chip Stocks to Buy in March 2024
Wager on these top blue-chip stocks to buy, striking an ideal balance between stability and growth for savvy long-term investors. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
93 94 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.